1. Migraine Prevention Therapy: Avoiding Overuse of Medications

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. Burden of Migraine

6. When to Consider Prevention

7. Use of Migraine Medication and Healthcare Resources: AMPP Study

8. Current Evidence-Based Migraine Prevention Treatments

9. Behavioral Preventive Therapy and Pharmacologic Treatment Adherence

10. Four Issues Affecting Current Prevention Therapy

11. Natural Fluctuations Between Episodic and Chronic Migraine: CaMEO

12. Risk Factors for Progression From Episodic to Chronic Migraine

13. ICHD-3 Beta Criteria: Medication Overuse Headache

14. Medication Use and Risk of Transformation From Episodic to Chronic Migraine

15. Chronic Migraine and Medication Overuse Headache

16. Combination Behavioral and Pharmacologic Treatment in Medication Overuse

17. Future of Migraine Prevention: CGRP as a Treatment Target

18. CGRP Receptor Blockers: Gepants

19. mAbs Targeting the CGRP Pathway

20. The 4 Anti-CGRP mAbs: Status Overview

21. Secondary Endpoints and Improvement in Function: Example of Erenumab

22. Anti-CGRP mAbs: Trial Endpoints

23. Reduction in Monthly Migraine Days in Episodic Migraine: Erenumab and Galcanezumab

24. Decrease in Monthly Migraine Days and Migraine Symptoms: Fremanezumab

25. Eptinezumab in Episodic Migraine and 75% Responder Rates in Chronic Migraine

26. Erenumab in Chronic Migraine

27. Safety of Anti-CGRP mAbs: Similar to Placebo

28. Reconsidering the 4 Issues Affecting Current Prevention Therapy: Anti-CGRP mAbs

29. Future of Migraine Prevention

30. Abbreviations